Skip to main content
Caplight Logo









Shenzhen Readline Biotechnology Co., Ltd.

Shenzhen Readline Biotechnology Co., Ltd.

Private
ShenzhenHealthcare & Life Scienceshttps://www.szreadline.com/

Last Round

Series C

Feb 21, 2025

Total Funding Raised

$157.56M

Company Overview

Shenzhen Readline Biotechnology Co., Ltd. is a biotechnology company that develops immobilized enzyme catalytic technology and provides active ingredients for the pharmaceutical, cosmetic, and nutritional supplement industries.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

IVDin-vitro diagnosticpoint-of-care testingPOCTrapid testingrapid diagnostic testlateral flow assayfluorescence immunoassaybedside testingdiagnostic hardwaresynthetic biologybiocomputingmedical device manufacturerlab-on-a-chipbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shenzhen Readline Biotechnology Co., Ltd. Comparables

Compare Shenzhen Readline Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Shenzhen Readline Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lansion Biotechnology Co., Ltd.
89%
Chengdu VACURE Biotechnology Co., Ltd.
86%
Assure Tech Hangzhou Co Ltd
78%

Shenzhen Readline Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 21, 2025
Series B ExtensionApr 14, 2023
Series BDec 9, 2022
Series A ExtensionNov 22, 2021
Series ADec 4, 2020
Angel
Jun 5, 2019

Key People

Founding team and executive leadership

JUNMEI WANG

总经理&创始人CEO&Co-Founder

Founding Team

Shenzhen Readline Biotechnology Co., Ltd. Investors

Notable investors and investment history

Shenzhen Readline Biotechnology Co., Ltd. investors
InvestorRounds
Oriental Fortune CapitalSeries B Extension, Series A Extension, Series B, Series A
Synergetic Innovation Fund ManagementSeries B Extension
Shenzhen Leaguer Co., Ltd.Series A
Shenzhen Leaguer Venture CapitalSeries A Extension
CoBuilder PartnersSeries A Extension
松禾资本 (Green Pine Capital Partners)Series B, Series C, Series A Extension
CoStone CapitalSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 15, 2026

    Grew 18% QoQ, from 40 to 47 employees.

  • Jan 21, 2026

    Monthly visitors grew 41% MoM.

Shenzhen Readline Biotechnology Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

Shenzhen Readline Biotechnology Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shenzhen Readline Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Is Shenzhen Readline Biotechnology Co., Ltd. a public or private company?

Shenzhen Readline Biotechnology Co., Ltd. is a private company.

What is the current stock price of Shenzhen Readline Biotechnology Co., Ltd.?

Shenzhen Readline Biotechnology Co., Ltd. is a private company with no public stock price. Caplight tracks Shenzhen Readline Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Shenzhen Readline Biotechnology Co., Ltd. worth (valuation)?

Valuation information for Shenzhen Readline Biotechnology Co., Ltd. is not publicly available.

Can I buy Shenzhen Readline Biotechnology Co., Ltd. stock?

Shenzhen Readline Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shenzhen Readline Biotechnology Co., Ltd.'s last funding round?

Shenzhen Readline Biotechnology Co., Ltd.'s most recent funding round was Series C on February 21, 2025.

Who are the main investors in Shenzhen Readline Biotechnology Co., Ltd.?

Key investors in Shenzhen Readline Biotechnology Co., Ltd. include Oriental Fortune Capital, 深圳市力合科创股份有限公司, 松禾资本 (Green Pine Capital Partners), CoStone Capital.

Will Shenzhen Readline Biotechnology Co., Ltd. IPO soon?

No public IPO plans have been announced for Shenzhen Readline Biotechnology Co., Ltd..

How can I track Shenzhen Readline Biotechnology Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shenzhen Readline Biotechnology Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShenzhen
Employee Range51
Year Founded2017
Last FundingFeb 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?